Jacobs Levy Equity Management’s Calithera Biosciences CALA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-36,063
Closed -$480K – 1129
2021
Q4
$480K Buy
36,063
+8,136
+29% +$204K ﹤0.01% 840
2021
Q3
$1.22M Buy
27,927
+18,147
+186% +$783K 0.01% 715
2021
Q2
$409K Sell
9,780
-1,744
-15% -$76.6K ﹤0.01% 900
2021
Q1
$558K Sell
11,524
-93
-0.8% -$5.41K ﹤0.01% 848
2020
Q4
$1.14M Sell
11,617
-932
-7% -$81.7K 0.01% 689
2020
Q3
$866K Sell
12,549
-3,067
-20% -$268K 0.01% 691
2020
Q2
$1.65M Buy
15,616
+3,537
+29% +$420K 0.02% 563
2020
Q1
$1.07M Buy
12,079
+4,467
+59% +$532K 0.01% 604
2019
Q4
$869K Buy
7,612
+5,321
+232% +$400K 0.01% 711
2019
Q3
$142K Sell
2,291
-2,570
-53% -$206K ﹤0.01% 870
2019
Q2
$379K Buy
4,861
+1,583
+48% +$180K 0.01% 783
2019
Q1
$442K Sell
3,278
-245
-7% -$25.7K 0.01% 791
2018
Q4
$283K Sell
3,523
-1,043
-23% -$103K 0.01% 818
2018
Q3
$479K Buy
4,566
+255
+6% +$24.3K 0.01% 788
2018
Q2
$431K Buy
4,311
+1,388
+47% +$157K 0.01% 829
2018
Q1
$368K Buy
2,923
+1,995
+215% +$311K 0.01% 831
2017
Q4
$155K Hold
928
– – ﹤0.01% 930
2017
Q3
$292K Hold
928
– – 0.01% 796
2017
Q2
$276K Sell
928
-238
-20% -$63.7K 0.01% 783
2017
Q1
$269K Buy
1,166
+63
+6% +$10.9K 0.01% 741
2016
Q4
$72K Buy
1,103
+275
+33% +$17.2K ﹤0.01% 925
2016
Q3
$54K Hold
828
– – ﹤0.01% 990
2016
Q2
$61K Sell
828
-1,092
-57% -$109K ﹤0.01% 1120
2016
Q1
$218K Buy
+1,920
New +$218K ﹤0.01% 953

Other funds holding CALA

Jacobs Levy Equity Management's CALA Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Calithera Biosciences (CALA) in Q1 2022, closing a stake of 36,063 shares — an estimated $480K sold.

Jacobs Levy Equity Management first reported a position in CALA in Q1 2016 and held it in 24 quarters. The position peaked at $1.65M in Q2 2020. 54 funds tracked by Wall St. Rank hold CALA as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining Calithera Biosciences position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 36,063 Calithera Biosciences shares in Q1 2022, an estimated $480K.
  • Jacobs Levy Equity Management first reported a position in Calithera Biosciences in Q1 2016 and held it in 24 quarters.
  • Jacobs Levy Equity Management's Calithera Biosciences position peaked at $1.65M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Calithera Biosciences as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.